Sanofi is selling its European generics business to Advent International for approximately €1.9 billion, as part of a continued effort to focus on its core areas of global medicines and emerging markets, specialty care and diabetes and cardiovascular. The deal is expected to close 4Q18 and the new business will be called Zentiva.  “We believe that Zentiva is a great platform, full of talented people, who we can invest behind to build a new, independent, European generics leader,” commented Ad...